

To: 5.1.2e <5.1.2e@rivm.nl>
Cc: 5.1.2e <5.1.2e@chemours.com>; restrictiePFAS <5.1.2l@rivm.nl>
From: 5.1.2e <5.1.2e@rivm.nl>
Sent: Thur 7/28/2022 1:31:47 PM
Subject: RE: [EXT] RE: Email for 5.1.2e - clarification on PFAS uses and emission data
Received: Thur 7/28/2022 1:31:57 PM

Thnx!

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: Thursday, July 28, 2022 3:25 PM
To: 5.1.2e <5.1.2e@chemours.com>
Cc: 5.1.2e <5.1.2e@chemours.com>; restrictiePFAS <5.1.2l@rivm.nl>
Subject: [EXT] RE: Email for 5.1.2e - clarification on PFAS uses and emission data

External email. Confirm links and attachments before opening.

Dear 5.1.2e,

I showed these figures as an illustration on our progress for the different use levels. As indicated they are preliminary results. In the restriction dossier we will clearly describe our finding regarding tonnages and emissions for the different use sectors; also specified for different PFAS subgroups. Of course, in our report proper definitions and references should be included.

Kind regards,

5.1.2e

.....
Centre for Safety of Substances and Products
National Institute for Public Health and the Environment
 Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven
 PO Box 1 (postbak 1) | 3720 BA Bilthoven | The Netherlands

.....
M 5.1.2e
 e-mail 5.1.2e <5.1.2e@rivm.nl>

Committed to health and sustainability




From: 5.1.2e <5.1.2e@chemours.com>
Sent: donderdag 28 juli 2022 15:07
To: 5.1.2e <5.1.2e@rivm.nl>
Cc: 5.1.2e <5.1.2e@chemours.com>
Subject: FW: Email for 5.1.2e - clarification on PFAS uses and emission data
Importance: High


Dear 5.1.2e,

A colleague of mine, 5.1.2e for the Thermal & Specialized Solutions business (F-gases), was present at the FPP4EU conference in June. I was alerted by him about the 2 slides below that you used (I believe they were also in your Chemcon presentation):

PFAS used in EU



PFAS emission in EU



Among the content presented, these slides illustrate the overview on the PFAS uses and the PFAS emissions on which we would like to get additional information. We are aware that the data presented are still preliminary results, but we would like to address you a set of questions to better understand and interpret the information you showed:

1. What is the source of the data presented for both uses and emissions? (e.g., answers to consultations, call for evidence reports...)
2. What are the absolute values presented for both tonnage of use and emissions data?
3. What applications do the "Transport"/"Transportation" and "Medical Devices"/"Medical Application" categories include?
4. What is the split among applications under the figure "Gaseous PFAS"?
5. The F-gases in scope depends on the PFAS definition used for the data presented. What definition was used?
6. Some F-gases quickly degrade once emitted and are not persistent. Some of them partly degrade to other PFASs. Was this taken into account and if yes, how were they considered in the split among Gaseous and non-gaseous PFAS?

We look forward to receiving your input and we remain at your disposal for any further clarification you might need.
Kind regards,

5.1.2e

M: 5.1.2e

T: 5.1.2e

Chemours Netherlands B.V.

Baanhoekweg 22
3313 LA Dordrecht



See our web page at <http://www.chemours.com> for a full directory of Chemours sites, staff, services and career opportunities.

This communication is for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use,

Chemours Netherlands B.V.

Baanhoekweg 22

3313 LA Dordrecht

Statutaire zetel: Dordrecht

Dossiernummer: 54013445

This communication is for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

<https://www.chemours.com/en/email-disclaimer>

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en *Committed to health and sustainability*

Chemours Netherlands B.V.

Baanhoekweg 22

3313 LA Dordrecht

Statutaire zetel: Dordrecht

Dossiernummer: 54013445

This communication is for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

<https://www.chemours.com/en/email-disclaimer>